Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | AGER | Q15109 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ASPH | Q12797 | 1/20 | 0.42 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29526925 | 1.00 | KDM4E (0.47) | KDM4EMAPTALDH1A1TSHRALOX15 | |
| Hydrochloric Acid SCHEMBL5755935 | 0.98 | KDM4E (0.46) | KDM4EMAPTALDH1A1TSHRALOX15 | |
| Potassium Ion SCHEMBL28215837 | 0.88 | KDM4E (0.40) | KDM4EMAPTALDH1A1TSHRALOX15 | |
| SCHEMBL5518273 | 0.82 | KDM4E (0.36) | KDM4EMAPTALDH1A1TSHRALOX15 | |
| SCHEMBL69939 | 0.81 | KDM4E (0.54) | KDM4EMAPTALDH1A1TSHRALOX15 | |
| SCHEMBL23864829 | 0.80 | KDM4E (0.35) | KDM4EMAPTALDH1A1TSHRALOX15 | |
| SCHEMBL335305 | 0.80 | SMN1; SMN2 (0.39) | KDM4EMAPTALDH1A1TSHRALOX15 | |
| SCHEMBL29364216 | 0.80 | SMN1; SMN2 (0.39) | KDM4EMAPTALDH1A1TSHRALOX15 | |
| SCHEMBL6345905 | 0.78 | KDM4E (0.52) | KDM4EMAPTALDH1A1TSHRALOX15 | |
| Water SCHEMBL335807 | 0.78 | KDM4E (0.52) | KDM4EMAPTALDH1A1TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117965239-A | Preparation method of solid aroma-diving substance and aroma-diving type cigarette lap adhesive | 河南中烟工业有限责任公司 | 2024-05-03 | — | — | CN | claimed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| WO-2018078657-A1 | PROCESS FOR PREPARATION OF GLIPIZIDE | J.B. CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2018-05-03 | — | — | WO | claimed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| EP-2493304-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. Lundbeck A/S (DK) | 2012-09-05 | — | — | EP | claimed |
| CN-102382066-A | Preparation method of 5-methylpyrazine-2-carboxylic acid | SUZHOU HONGRUI MEDICAL TECHNOLOGY CO LTD | 2012-03-21 | — | — | CN | claimed |
| EP-2086972-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2009-08-12 | — | — | EP | claimed |
| EP-2018371-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-01-28 | — | — | EP | claimed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| WO-2008064265-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| WO-2007136703-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| US-20040053989-A1 | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | PATRICK PRENDERGAST (IE) | 2004-03-18 | — | — | US | claimed |
| WO-2001009118-A2 | DITHIOLTHIONE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS AND FOR MEMORY ENHANCEMENT | PRENDERGAST PATRICK T (IE) | 2001-02-08 | — | — | WO | claimed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | disclosed |
| EP-4616913-A2 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-0722932-B1 | Process for preparing tertiary amine-N-oxide | KOEI CHEMICAL CO (JP) | 1999-05-12 | — | — | EP | disclosed |
| WO-1998017648-A1 | ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS | XENOVA LIMITED (GB) | 1998-04-30 | — | — | WO | disclosed |
| US-5668281-A | Process for preparing tertiary amine-N-oxide | KOEI CHEMICAL CO., LTD. (JP) | 1997-09-16 | — | — | US | disclosed |
| EP-0722932-A1 | Process for preparing tertiary amine-N-oxide | KOEI CHEMICAL CO., LTD. (JP) | 1996-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KDM4E 331/4885MAPT 3934/4885ALDH1A1 1223/4885 |
| US-20040053989-A1 | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | PNMT, CHAT, MAPT | KDM4E 1675/4885MAPT 3/4885ALDH1A1 243/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | KDM4E 1621/4885MAPT 3633/4885ALDH1A1 1008/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | KDM4E 3646/4885MAPT 150/4885ALDH1A1 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.